Univariate analysis of factors potentially associated with TRM including day 28 ST2 level in 113 DCBT recipients
| Variable . | N . | Day 180 TRM, % (95% CI) . | P . |
|---|---|---|---|
| Age, y | |||
| 0-15 | 15 | 0 (NA) | .034 |
| ≥16 | 98 | 16 (10-24) | |
| Recipient CMV serostatus | |||
| Seronegative | 52 | 2 (0-9) | .013 |
| Seropositive | 61 | 25 (15-36) | |
| Conditioning | |||
| Myeloablative | 84 | 13 (7-21) | .632 |
| Nonmyeloablative | 29 | 17 (6-33) | |
| Dominant unit TNC dose | |||
| <2.22 × 107/kg | 56 | 14 (7-25) | .654 |
| ≥2.22 × 107/kg | 57 | 14 (7-24) | |
| Dominant unit CD34+cell dose | |||
| <1 × 105/kg | 56 | 14 (7-25) | .363 |
| ≥1 × 105/kg | 57 | 14 (7-24) | |
| Dominant unit-recipient 6 allele HLA match | |||
| Worse HLA match: 2-3/6 | 30 | 20 (8-36) | .153 |
| Better HLA match: 4-6/6 | 83 | 12 (6-20) | |
| ST2 level, ng/mL | |||
| Low: ≤33.9 | 57 | 5 (1-13) | .001 |
| High: >33.9 | 56 | 23 (13-35) |
| Variable . | N . | Day 180 TRM, % (95% CI) . | P . |
|---|---|---|---|
| Age, y | |||
| 0-15 | 15 | 0 (NA) | .034 |
| ≥16 | 98 | 16 (10-24) | |
| Recipient CMV serostatus | |||
| Seronegative | 52 | 2 (0-9) | .013 |
| Seropositive | 61 | 25 (15-36) | |
| Conditioning | |||
| Myeloablative | 84 | 13 (7-21) | .632 |
| Nonmyeloablative | 29 | 17 (6-33) | |
| Dominant unit TNC dose | |||
| <2.22 × 107/kg | 56 | 14 (7-25) | .654 |
| ≥2.22 × 107/kg | 57 | 14 (7-24) | |
| Dominant unit CD34+cell dose | |||
| <1 × 105/kg | 56 | 14 (7-25) | .363 |
| ≥1 × 105/kg | 57 | 14 (7-24) | |
| Dominant unit-recipient 6 allele HLA match | |||
| Worse HLA match: 2-3/6 | 30 | 20 (8-36) | .153 |
| Better HLA match: 4-6/6 | 83 | 12 (6-20) | |
| ST2 level, ng/mL | |||
| Low: ≤33.9 | 57 | 5 (1-13) | .001 |
| High: >33.9 | 56 | 23 (13-35) |